Flputnam Investment Management Co. decreased its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 13.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 19,048 shares of the conglomerate’s stock after selling 2,884 shares during the quarter. Flputnam Investment Management Co.’s holdings in Danaher were worth $4,372,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently added to or reduced their stakes in the company. Kovack Advisors Inc. increased its position in Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the period. Gilbert & Cook Inc. increased its holdings in shares of Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after purchasing an additional 42 shares during the period. Grimes & Company Inc. increased its holdings in shares of Danaher by 0.6% in the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after purchasing an additional 43 shares during the period. Harbour Investments Inc. increased its holdings in shares of Danaher by 3.0% in the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after purchasing an additional 45 shares during the period. Finally, Dakota Community Bank & Trust NA increased its holdings in shares of Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after purchasing an additional 45 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Activity at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 11.10% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on DHR
Danaher Stock Up 1.0 %
DHR opened at $207.73 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market cap of $148.47 billion, a P/E ratio of 39.34, a PEG ratio of 2.66 and a beta of 0.83. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The business’s fifty day simple moving average is $224.58 and its 200 day simple moving average is $244.92.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the company earned $2.09 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Where to Find Earnings Call Transcripts
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How Can Investors Benefit From After-Hours Trading
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- About the Markup Calculator
- MarketBeat Week in Review – 02/24 – 02/28
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.